Abstract
Objective. Carvedilol is an α-and β-blocking agent with antioxidant properties. We examined if treatment with carvedilol in vivo protected the heart against ischemic injury ex vivo. Methods. Isolated hearts from treated rats (80 mg/kg/day) were subjected to 30 min regional ischemia. Hearts from non-treated animals received either no drug, 10 min carvedilol (1 µM) acute or ischemic preconditioning (IP) by 5 min ischemia +5 min reperfusion prior to regional ischemia. In separate experiments isolated hearts were subjected to 15 min global ischemia and 30 min reperfusion. Results. Infarct size was significantly reduced by ischemic preconditioning or by chronic carvedilol treatment (9.0±0.9% and 7.2±1.9% of risk zone infarcted, respectively, vs. 33.8±6.4% in control hearts, mean±SEM, p < 0.05). Recovery of left ventricular developed pressure after global ischemia was not improved by carvedilol. Post-ischemic rise in left ventricular end diastolic pressure was, however, attenuated by chronic carvedilol treatment. Conclusion. Chronic in vivo but not acute ex vivo pretreatment with carvedilol significantly limited infarct size in isolated rat hearts.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
